Annual Revenue Comparison: Exelixis, Inc. vs Pharming Group N.V.

A Decade of Growth: Exelixis, Inc. vs Pharming Group N.V.

In the ever-evolving landscape of biotechnology, Exelixis, Inc. and Pharming Group N.V. have emerged as notable players. Over the past decade, Exelixis has demonstrated a remarkable revenue growth trajectory, increasing its annual revenue by over 7,000% from 2014 to 2023. This surge is largely attributed to its successful oncology products. In contrast, Pharming Group N.V. has shown a steady, albeit more modest, growth of approximately 850% during the same period, driven by its niche focus on rare diseases.

Key Insights

• Exelixis, Inc.: From 2014 to 2023, Exelixis' revenue skyrocketed, peaking at $1.83 billion in 2023.
• Pharming Group N.V.: Despite a slower pace, Pharming's revenue reached $245 million in 2023, reflecting consistent growth.

This comparison highlights the diverse strategies and market dynamics within the biotech sector, offering valuable insights for investors and industry enthusiasts.